Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

Back to Contracts

Illumina Reagent Kits

Active

1301397256Federal

Response Deadline08/07/2026, 08:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Defense → Naval Medical Research CenterView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Frederick, MD, 21702, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedJul 23

special-notice

Response DeadlineAug 7

Submission deadline

Response Deadline

08/07/2026, 08:00:00 PM UTCin 14 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Defense → Naval Medical Research Center

Contacts2 people available

OfficeSILVER SPRING, MD, 20910-7500, USA

Organization / Agency

Department Of Defense → Naval Medical Research Center

View Agency Profile

Office AddressSILVER SPRING, MD, 20910-7500, USA

Contacts

Shamai Carter

contact@example.gov

Nataki JOHNSON

contact@example.gov

Full Description

Show more

The United States Department of the Naval Medical Research Command (NMRC) intends to award a sole source contract to, Illumina, Inc., San Diego, CA 92122-4616. This notice is not a request for competitive proposals however If interested Government shall consider all responses.

Requirement: Purchase of Illumina Reagent Kits

The NAICS code for this action is 541714. This requirement will be procured under the guidelines of FAR Part 12 Commercial Items. NMRC requires that all contractors doing business with the Acquisition Office must be registered with the Systems for Award Management (SAM). No award can be made unless the vendor is registered in Systems for Award Management. For additional information and to register in SAM, please access the following website: https://www.sam.gov/. In order to register with the SAM and to be eligible to receive an award from this Acquisition Office, all offers must have a Unique Entity Identification Number (UEI). A Sam.gov number may be acquired free of charge by contacting Sam.gov online at www.sam.gov or by phone at (866) 606-8220.

Similar Contracts

Same NAICS industry code

Battlefield Pain Management – AnalgesicThis solicitation under the Prototype Other Transaction Authority (10 U.S.C. § 4022) seeks innovative analgesic solutions for battlefield use, with the goal of achieving FDA approval for a single-use product intended to manage acute moderate to severe pain in combat settings. The product must be rapid to administer, compact in size and weight for individual carrying, and capable of functioning without refrigeration across extreme temperatures ranging from -25°C to 45°C while maintaining a 2-3 year shelf life at controlled room temperature. It must comply with USP <659> and MIL-STD-810 environmental standards, adhere to 21 CFR Part 820 quality system requirements for labeling and packaging, and meet strict physiological limits including no more than a 20% reduction in blood pressure, heart rate, or clotting ability, with only minor, non-ventilation-required airway changes. The product must be classified as a DEA Schedule II or higher controlled substance and may be delivered via nasal spray or autoinjector. The effort spans eight years, divided into three phases: three years for Chemistry Manufacturing Controls and stability studies, two years for non-clinical enabling studies, and three years for clinical trials and human factors testing culminating in potential EUA submission. The contract is structured as an Other Transaction Agreement exempt from FAR and DFARS, except where explicitly referenced, and is not subject to Bayh-Dole provisions. Proposals must demonstrate at least one of three pass/fail conditions: inclusion of a significant nontraditional defense contractor or nonprofit research institution, all non-federal participants being small businesses or nontraditional contractors, or at least one-third of project costs being privately funded. Evaluation focuses on technical approach, management strategy, and cost, with no assigned weights provided. Submission requires three clearly organized volumes in searchable PDF format, accompanied by a Microsoft Project plan, with strict formatting rules prohibiting embellishments. All participants must be registered in SAM with an active UEI and CAGE code, and must include NAICS code 541714. Compliance with prohibitions on malign foreign talent programs is mandatory, requiring certification and disclosure of foreign affiliations, ownerships, and funding sources. Payment occurs through WAWF using NPI, cost vouchers, or invoices tied to CLINs and ACRNs, with acceptance managed by an Agreement Officer Representative. Data deliverables, including CMC reports, clinical study outcomes, and regulatory filings, are governed by CDRL and DID attachments

Defense Health Agency

POSTED

DEADLINE

Development of Light-Responsive Artificial Cells using Plant-Based Photoreceptor SystemsThe United States Army Corps of Engineers Engineer Research and Development Center Construction Engineering Research Laboratory is seeking to develop light-responsive artificial cells by integrating plant-derived UVR8 photoreceptor systems into synthetic biology platforms, using high-throughput protein engineering and AI-assisted structural refinement to create programmable, pseudo-living systems activated by environmental light stimuli. The project aims to advance foundational science in synthetic biology by leveraging Bioconscientia, LLC’s uniquely specialized expertise in UVR8 photoreceptor technology, which enables precise sensing of UV-B light in a manner unmatched by other entities. Due to the highly specialized nature of the required research and Bioconscientia’s irreplaceable knowledge of existing experimental data and technical pathways, the government intends to award a sole-source contract to this vendor under RFO FAR 12.102(a), with an anticipated award date of September 30, 2026. This presolicitation notice, issued under FAR Part 5.101(a) with solicitation number W9132T26QA015 and NAICS code 541714, does not constitute a formal request for proposals or a competitive procurement, nor is it a set-aside. Interested parties may submit capability statements to CERL-CT-QUOTES@USACE.ARMY.MIL by July 31, 2026, to be reviewed for potential technical equivalency, but submission does not guarantee a change to the government’s acquisition strategy. The government retains full discretion to proceed with sole-source award regardless of responses received. All work will be performed in Champaign, Illinois, and the primary point of contact for submissions is Lurline L. Simmons, with Andrea J. Thomas serving as the contracting officer. No telephone inquiries will be accepted.

W2R2 Construction Engrg Labor

POSTED

DEADLINE

AI/ML and Data Analytics for Cardiovascular Device Validation

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is soliciting collaborative participation through a continuous, open Participant Basic Agreement (PBA) under the HEALER portfolio to advance next-generation, threat-agnostic host-directed therapeutics designed to enhance physiological resilience against CBRN threats. This initiative targets five critical biological systems—neurological protection, respiratory stabilization, immune modulation, hematologic and vascular function, and cellular stress and repair pathways—with the goal of developing dual-use medical countermeasures that serve both military and civilian critical care needs. The program invites two categories of collaborators: therapeutic developers with candidates that modulate host response mechanisms and drug development support providers including CROs and CDMOs with capabilities in preclinical testing, clinical trial execution, cGMP manufacturing, regulatory strategy, and advanced modeling. Submission requires a white paper of no more than five pages excluding a cover page, detailing product mechanism of action, efficacy data from validated animal models, regulatory status such as IND experience and clinical trial history, manufacturing capacity and scale-up plans, and company profile for therapeutic developers, or core capabilities and infrastructure for service providers. All participants must express willingness to collaborate with other PBA holders to foster an integrated development ecosystem. The solicitation, issued under statutory authority of 10 U.S.C. §§4021–4023, operates outside the Competition in Contracting Act and does not follow traditional procurement or evaluation frameworks, eliminating standard contract clauses, formal evaluation factors, pricing structures, or submission deadlines. Instead, awards are made at the government’s discretion through a non-traditional acquisition mechanism designed to accelerate innovation. Technical and administrative inquiries are directed to Hunter Robinson and Alexander Mayatte at the U.S. Army’s Aberdeen Proving Ground, Maryland office. Participation prerequisites include current registration in the System for Award Management (SAM), compliance with FDA regulatory pathways, and adherence to cGMP standards for manufacturing. While no specific delivery dates, FOB terms, inspection criteria, or cost estimates are defined, performance is expected to align with the mission of CPE CBRND to enable the Joint Force to operate effectively in CBRN-contested environments. Intellectual property considerations, teaming arrangements, and the scalability of therapeutic candidates are central to selection, with no socioeconomic or size status certifications required. The structure prioritizes agility, collaboration, and cross-sector innovation over rigid compliance, enabling a dynamic pipeline of medical countermeasures capable of addressing evolving biological threats through sustained host resilience.

POSTED

DEADLINE

Non-Optical Methods for High Speed Protein ControlDARPA’s Biological Technologies Office is seeking innovative solutions through the ERIS Marketplace to develop a new class of rapidly switchable, non-optogenetic protein domains capable of enabling real-time, massless control of cellular processes. The goal is to create a robust, modular molecular tool that responds to non-optical external signals such as magnetic fields or focused ultrasound, allowing precise regulation of protein function across cell membranes without relying on light or chemicals. Proposed solutions must achieve activation and deactivation kinetics of no more than two seconds, demonstrate reliable performance through at least 300 repetitive cycles in living cells, and function effectively in both split-protein dimerization and allosteric conformational configurations. This effort explicitly excludes any modifications or enhancements to existing optogenetic, light-based, or chemical systems. The anticipated contract value is $400,000 for a 12-month performance period, with awards being made on a rolling basis as solutions are evaluated, and the government reserves the right to issue awards before the December 8, 2026 submission deadline. Proposals must be submitted via the DARPA Connect ERIS Portal as a video that follows the required title format, or existing awardable solutions may be flagged for consideration by emailing ERIS@darpa.mil with specific subject and body requirements. Evaluation will focus on four core areas: a deep understanding of the problem space and current limitations in fields like sonogenetics and magnetogenetics, a significant technical leap in achieving rapid and repeatable protein control, demonstrated expertise in synthetic biology, protein engineering, and biophysics with a proven track record of quantitative in vivo characterization, and the potential of the solution to become a foundational tool in synthetic biology with broad applications in defense-relevant areas such as biomanufacturing, cell-based therapeutics, and biosensing. All submissions are subject to the ERIS assessment process, which serves as a mandatory pass/fail gate—only solutions deemed awardable by this process will be considered for BTO award. The procuring agency is the Department of Defense through DARPA’s Arlington, VA office, and all participants must comply with the ERIS Master Solicitation requirements available via SAM.gov.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Notice of Intent to Sole Source – University of Maryland Medical Center

National Institutes Of Health - Cc

POSTED

DEADLINE

Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration AwardThe Congressionally mandated Clinical and Translational Science Awards (CTSA) Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by funding a national network of academic medical centers. This network provides essential infrastructure, expertise, training, and collaborative platforms needed to move research from the laboratory into clinical practice and community health settings. The current opportunity is a forecast for a limited competition soliciting applications for the Collaborative and Innovative Acceleration Award, designed to support the development and implementation of novel approaches, technologies, or models that amplify the impact of translational research and expedite the delivery of effective therapies to all populations. Funding is authorized under Sections 301 and 405 of the Public Health Service Act, and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Eligible organizations may apply under this limited competition, and proposals will undergo standard National Institutes of Health peer review, with funding awarded only to meritorious applications. The announcement is issued by the National Institutes of Health, under the Department of Health and Human Services, with specific inquiries directed to the Division of Clinical Innovation at NCATS. The forecast was posted on July 20, 2026, and further details can be accessed through the official grants.gov listing, though no set-aside type, NAICS code, or specific place of performance is indicated.

National Institutes Of Health

POSTED

DEADLINE

On-Site Technical Deployment and Integration

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber ServicesNASA Johnson Space Center is soliciting offers for Hypoxia Chamber Services under solicitation number 80JSC026Q0008 to support research on the physiological, cognitive, and clinical effects of mild hypobaric hypoxia as part of the Artemis Program. The contract requires comprehensive services including infrastructure, personnel, training, materials, food, supplies, and operational support necessary to conduct controlled hypoxia experiments. This is a combined synopsis and solicitation issued under FAR Subpart 12.6, with no written solicitation to follow, and all information is contained within the posted notice and attachments, particularly Attachment A for the Performance Work Statement and Attachment D for additional submission requirements. The NAICS code is 541714 with a size standard of 1,000 employees, and offerors must self-certify their size status. Evaluation will prioritize Technical Acceptability and Past Performance as significantly more important than Price, though Price becomes increasingly relevant when proposals are closely matched in technical merit. All submissions must include completed representations and certifications per FAR 52.212-3 and comply fully with FAR 52.212-1 and 52.212-4. Proposals must be submitted electronically via email to the designated NASA contacts no later than 1:00 PM CST on August 24, 2026, with questions due by July 29, 2026. The Government assumes no responsibility for electronic submission failures, and late submissions will be rejected per FAR provisions. The place of performance is Houston, Texas, and the Ombudsman clause is applicable for dispute resolution.

NASA Johnson Space Center

POSTED

DEADLINE

in about 1 month

Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain BarrierThe Eunice Kennedy Shriver National Institute of Child Health and Human Development is advancing its mission to improve maternal, fetal, and child health by launching a second phase of the Transporter Elucidation Network, focused on understanding how biological transporters and local metabolic processes regulate exposure to nutrients, medications, microbiome-derived compounds, and environmental chemicals across critical perinatal barriers. This initiative will develop comprehensive multi-barrier frameworks that connect the maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier, building on prior organ-specific research to create standardized models, resources, and prototype multi-compartment systems that reflect the dynamic interplay of transporters, their polarity, kinetics, and biotransformation capacities during pregnancy, lactation, and infant development. The goal is to deepen mechanistic insights into how these systems influence nutrient delivery, drug distribution, and neurodevelopmental outcomes in early life. This phase will establish community-wide resources to support integrated studies of perinatal exposure, risk assessment, and targeted interventions across linked maternal-fetal-infant systems, while strengthening collaboration among researchers and accelerating the sharing of tools and data. Emphasis is placed on human-based and developmentally relevant models to ensure biological accuracy and translational impact. The effort also aims to cultivate a next-generation workforce skilled in transporter science, fostering innovation in pediatric pharmacology and neonatal health. Authorized under 42 U.S.C. § 241, the initiative is being led by the Obstetric and Pediatric Pharmacology and Therapeutics Branch of NICHD, with inquiries directed to their designated point of contact, and the opportunity was publicly forecasted on July 16, 2026.

National Institutes Of Health

POSTED

DEADLINE

Advanced Prebreathe and Thermal Monitoring Studies

NASA Johnson Space Center

POSTED

DEADLINE

in about 1 month

Hypobaric Chamber Pilot StudiesNASA Johnson Space Center is soliciting offers for pilot chamber testing facilities capable of conducting hypobaric Decompression Sickness (DCS) studies under solicitation number 80JSC026Q0006, issued as a combined synopsis and solicitation per FAR Part 12 for commercial products and services. The requirement calls for three test days of data collection and recording following established research protocols, with detailed specifications outlined in Attachment A – Statement of Work and additional submission criteria in Attachment D dated July 15, 2026. The solicitation is open to all responsible sources without set-aside restrictions, and offerors must declare their size status under NAICS code 541714 with a 1,000-employee size standard. Evaluation of proposals will prioritize technical acceptability, followed by past performance, and then price, as specified in FAR 52.212-2. Offers must comply with applicable clauses including FAR 52.212-1, 52.212-2, and 52.212-4, as well as NASA-specific clauses such as the Ombudsman provision. All submissions must be delivered electronically to Tracy.L.Quintanilla@nasa.gov and Katelyn.R.Jaime@nasa.gov no later than August 24, 2026, at 1:00 p.m. Central Time. Questions must be submitted via email by July 29, 2026, same time, with no telephone inquiries accepted. Prospective offerors are encouraged to notify the point of contact of their intent to respond, and it is the offeror’s responsibility to download all documents from SAM.gov and ensure timely submission, as late or incomplete offers will be rejected in accordance with FAR provisions.

NASA Johnson Space Center

POSTED

DEADLINE

in about 1 month

More opportunities from Department Of Defense → Naval Medical Research Center

Same awarding agency

Reagents for sequencing in MiSeq and MiniSeq platformsThe U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH) in Callao, Peru, is seeking reagents to support next-generation sequencing activities on Illumina MiSeq and MiniSeq platforms using human samples. The required materials include a Nextera XT DNA Sample Preparation Kit for low-input library construction (~50ng DNA) with integrated enzymatic fragmentation, end-repair, A-tailing, and ligation steps, along with dual indexing at both ends for sample identification. The sequencing kits must support at least 150 cycles with paired-end read capability, deliver over 2.0 Gb per run with high Q30 quality, and include internal controls to validate sequencing performance. Specific products include the PhiX control v3 kit, MiSeq Reagent Kit v3 (600-cycle), MiniSeq High Output Reagent Kit (300-cycle), and two sets of Nextera XT Index Kit v2 for 384 samples each. All items must be shipped immediately upon contract award to Callao, Peru, under strict cold chain conditions due to time-sensitive expiration dates. The vendor is required to provide expiration date information to the government prior to shipment and obtain approval before delivery. None of the reagents are classified as hazardous materials. The solicitation, identified as VEID260013, is issued as an 8(a) Sole Source under NAICS code 424210 by the Naval Medical Research Center in Silver Spring, Maryland, with a response deadline of July 29, 2026. Point of contact for inquiries includes Luciana Encinas and Shamai Carter.

Drugs and Druggists' Sundries Merchant Wholesalers

POSTED

DEADLINE

Reagents for HAI and Enteric studiesThe contract covers a comprehensive suite of microbiological reagents and diagnostic kits designated for use in Healthcare-Associated Infection (HAI) and enteric pathogen studies. It includes multiple API 20 test strips for bacterial identification, such as API 20 E for Enterobacteriaceae, API 20 NE for non-Enterobacteriaceae, API 20 Staph for staphylococci, and API 20 Strep for streptococci, each supplied with accompanying media and organized in quantities ranging from four to fourteen kits. Complementary biochemical tests are also specified, including Nitrate, VP, TDA, Zinc, ZYM A, ZYM B, NIN, and James reagents, each in quantities of three units, alongside mineral oil and NG Test Carba 5 carbapenemase detection strips in a quantity of twenty. Additionally, the contract includes ETEST antimicrobial susceptibility strips for ciprofloxacin, trimethoprim/sulfamethoxazole, azithromycin, ampicillin, erythromycin, and ceftriaxone, all in quantities of four per item, supporting detailed antimicrobial resistance profiling. The set is tailored for laboratory applications requiring precise pathogen identification and antimicrobial susceptibility determination. The solicitation is issued under the title Reagents for HAI and Enteric studies with solicitation number BAC260018, published on July 14, 2026, with a response deadline of July 29, 2026. This is an 8(a) Sole Source contract, administered by the Naval Medical Research Center under the Department of Defense, located in Silver Spring, Maryland, with performance required in Callao. The procurement falls under NAICS code 424210, indicating wholesale trade of medical and surgical equipment and supplies. Primary point of contact is Luciana Encinas, with Shamai Carter as secondary contact, both reachable via email and phone. The contract is accessible through the SAM.gov portal for further details and submission requirements.

Drugs and Druggists' Sundries Merchant Wholesalers

POSTED

DEADLINE

Comprehensive full-service maintenance/repair plan for Illumina Nova/Seq 6000The Department of the Naval Medical Research Command plans to award a sole source contract to Illumina Inc. for a comprehensive full-service maintenance and repair plan for the Illumina NovaSeq 6000 system, specifically unit S/N A01716. This one-year contract includes four identical Silver Support Plans tailored to this specific equipment, ensuring coverage that meets stringent manufacturer standards. Key services encompass full OEM parts replacement, labor, and travel by certified technicians, no-cost replacement of proprietary reagents lost due to hardware failure, and at least one on-site preventative maintenance visit annually that aligns with OEM requirements. Additional provisions include remote technical support available Monday through Friday from 6:00 a.m. to 6:00 p.m., on-site technician response within two business days for any hardware performance issues, and control software and hardware updates as specified by the OEM. The contract also features on-site applications support, remote monitoring, and discounted advanced training for laboratory operators. The solicitation, identified by number N3239826Q4072, is managed by the Naval Medical Research Center, based in Silver Spring, Maryland, with submission deadline set at the end of 2026. The primary contacts for this procurement are Deborah Sharpe and Stephanie Gray.

Electronic and Precision Equipment Repair and Maintenance

POSTED

DEADLINE

Supply of OEM-Compliant Replacement Parts & ReagentsThis contract involves the supply of OEM-authorized replacement parts and reagents for the NovaSeq 6000 system, specifically including components such as flow cells and optics. It ensures the provision of reagents with a no-cost replacement policy for any lost or damaged items, while also requiring strict adherence to FDA safety updates throughout the contract term. The primary objective is to maintain the functionality and compliance of the equipment used by the Naval Medical Research Center. Issued by the Department of Defense through the Naval Medical Research Center, the subcontract focuses on maintaining essential inventory for the NovaSeq 6000 in Silver Spring, with a relevant NAICS code of 423490. The contract was posted in late December 2025, with responses due by the end of 2026, allowing adequate time for interested suppliers to submit proposals. This arrangement supports the critical biomedical research capabilities of the military medical research entity by ensuring uninterrupted access to reliable replacement parts and reagents.

Other Professional Equipment and Supplies Merchant Wholesalers

POSTED

DEADLINE

On-Site Remedial Repairs & Emergency ResponseThe contract involves providing emergency on-site repair services for the NovaSeq 6000 system, ensuring that response times do not exceed two business days. The primary objective is to restore the equipment to original equipment manufacturer (OEM) operational standards using only authorized parts, guaranteeing high-quality and reliable repairs. This work is being conducted under a subcontract for the Department of Defense, specifically for the Naval Medical Research Center, with the place of performance located in Silver Spring, Maryland. The solicitation was posted on December 22, 2025, and responses are due by December 31, 2026. It falls under NAICS code 811211, which relates to equipment repair services. There are no specified set-aside requirements or organization type restrictions associated with this subcontract. The comprehensive nature of the contract emphasizes prompt emergency response and adherence to strict quality standards to maintain critical medical research operations.

Consumer Electronics Repair and Maintenance

POSTED

DEADLINE

Remote Technical Support & Monitoring ServicesThis contract entails providing remote technical support and system monitoring services for the NovaSeq 6000 system during designated business hours. The scope includes troubleshooting, performing software updates, and conducting diagnostics using secure original equipment manufacturer (OEM) tools to ensure optimal system performance. The services are aimed at maintaining the operational readiness and reliability of the equipment through proactive management and timely issue resolution. Issued by the Naval Medical Research Center under the Department of Defense, this subcontract opportunity falls under the NAICS code 541512, which pertains to computer systems design services. The place of performance is located in Silver Spring, with the deadline for responses set for December 31, 2026. This contract represents an important technical support role critical to sustaining advanced research capabilities within a government medical research environment.

Computer Systems Design Services

POSTED

DEADLINE

Quarterly On-Site Preventive Maintenance & Calibration ServicesThe contract entails providing quarterly on-site preventive maintenance, calibration, and safety testing services for the Illumina NovaSeq 6000 DNA sequencing instrument located at Fort Detrick, Maryland. These services must be performed using original equipment manufacturer (OEM)-certified technicians and tools to ensure proper upkeep and accuracy. The work supports the Naval Medical Research Center, a Department of Defense agency, and aligns with NAICS code 811211, which relates to equipment maintenance. The contract is classified as a subcontract with no set-aside status specified. The solicitation was posted on December 22, 2025, with a response deadline of December 31, 2026. Although the exact office location is unspecified, the place of performance is indicated as Silver Spring, Maryland, zip code 20910. This effort is critical to maintaining the operational readiness and reliability of high-precision DNA sequencing equipment essential to the agency's research objectives.

Consumer Electronics Repair and Maintenance

POSTED

DEADLINE